# Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

*PRI Rank #8 · Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/rank-8*

| Field | Value |
| --- | --- |
| Rank | #8 |
| 18m citations | 160 |
| Journal | The Lancet |
| Year | 2024 |
| DOI | 10.1016/s0140-6736(24)00319-2 |
| Corresponding authors | Sandra P. D’Angelo |
| Institution | Memorial Sloan Kettering Cancer Center, United States |

**Ranking page:** [Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026](https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026)

**Paper link:** [10.1016/s0140-6736(24)00319-2](https://doi.org/10.1016/s0140-6736(24)00319-2)

## Topics

afamitresgene autoleucel · synovial sarcoma · myxoid round cell liposarcoma · SPEARHEAD-1 · Phase II clinical trial · open-label trial · advanced sarcoma · autologous CAR T cell therapy · TCR-T cell therapy

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-21.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```